Simplicity Wealth LLC Buys New Stake in Elevance Health, Inc. $ELV

Posted by Geri Gentry on Aug 18th, 2026

Simplicity Wealth LLC purchased a new position in Elevance Health, Inc. (NYSE:ELV – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,914 shares of the company’s stock, valued at approximately $740,000.

Several other institutional investors have also bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new stake in shares of Elevance Health in the 4th quarter worth about $31,000. J.Safra Asset Management Corp bought a new position in shares of Elevance Health in the 4th quarter valued at about $32,000. WealthCollab LLC grew its position in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after acquiring an additional 27 shares in the last quarter. Elevation Wealth Partners LLC increased its stake in Elevance Health by 600.0% during the second quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after acquiring an additional 90 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Elevance Health during the fourth quarter worth approximately $38,000. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

ELV has been the subject of several analyst reports. TD Cowen raised their price objective on Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Elevance Health in a research report on Thursday. Jefferies Financial Group decreased their price target on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Cantor Fitzgerald lifted their price objective on shares of Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Finally, UBS Group boosted their price objective on shares of Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $440.90.

Get Our Latest Stock Analysis on ELV

Insider Buying and Selling at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.

Elevance Health Trading Down 2.4%

ELV opened at $390.69 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. The stock’s 50 day moving average price is $395.48 and its 200-day moving average price is $358.49. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $436.24. The stock has a market cap of $84.73 billion, a price-to-earnings ratio of 17.36, a P/E/G ratio of 2.30 and a beta of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. During the same period last year, the company earned $8.84 EPS. Elevance Health’s quarterly revenue was up .8% compared to the same quarter last year. On average, equities analysts forecast that Elevance Health, Inc. will post 27.07 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be paid a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.